Travere Therapeutics, Inc.
TVTX
$42.84
-$0.67-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.92% | -21.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.92% | -21.33% | |||
| Cost of Revenue | 38.79% | 12.99% | |||
| Gross Profit | -37.43% | -37.81% | |||
| SG&A Expenses | -21.08% | 17.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.23% | 15.86% | |||
| Operating Income | -13.84% | -230.07% | |||
| Income Before Tax | -74.33% | -181.92% | |||
| Income Tax Expenses | -113.03% | 11,412.50% | |||
| Earnings from Continuing Operations | -66.48% | -185.53% | |||
| Earnings from Discontinued Operations | -102.02% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,459.55% | -89.38% | |||
| EBIT | -13.84% | -230.07% | |||
| EBITDA | 18.11% | -135.10% | |||
| EPS Basic | -1,437.42% | -89.52% | |||
| Normalized Basic EPS | -71.33% | -180.96% | |||
| EPS Diluted | -1,437.42% | -89.03% | |||
| Normalized Diluted EPS | -71.33% | -193.10% | |||
| Average Basic Shares Outstanding | 1.74% | 1.19% | |||
| Average Diluted Shares Outstanding | 1.74% | -12.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||